Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Currently there is no approved pharmacotherapy for amphetamine dependence. Recent human laboratory studies have demonstrated that naltrexone modulates some of the reinforcing effects of amphetamine. The aim of this study was to investigate the efficacy of naltrexone in comparison with placebo in reducing relapse to amphetamine use in amphetamine-dependent patients. METHOD: Eighty patients who met DSM-IV criteria for amphetamine dependence were randomized to 12 weeks of double-blind naltrexone (50 mg) or placebo treatment. Patients visited the clinic twice weekly to receive medication and relapse prevention therapy and leave urine samples, which were analyzed for drug toxicology and for assessing adherence to medication via detection of naltrexone's metabolite (6-beta-naltrexol). The main outcome measure was abstinence from amphetamine use, as indicated by the total number of negative amphetamine urine samples during 12 weeks of treatment. All missing urine samples were defined for the analysis as positive for amphetamine. RESULTS: Overall, 55 patients (68.8%) completed the trial. The intention-to-treat analysis showed that the naltrexone group had a significantly higher number of amphetamine-negative urine samples compared with the placebo group. Survival analyses showed that the treatment groups differed in rate of continuous abstinence, in both the intention-to-treat and completer samples, in favor of naltrexone treatment. There was a significant reduction in craving levels and self-reported consumption of amphetamine in the naltrexone group compared with the placebo group. Treatment with naltrexone was well tolerated in this sample. CONCLUSIONS: This trial demonstrated the efficacy of naltrexone in reducing amphetamine use in amphetamine-dependent individuals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A randomized controlled trial of naltrexone (50mg/d) for amphetamine use disorder showed significantly greater reductions in craving ratings compared to placebo (50).”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [50]
In the citing paper
“Significantly greater reduction in craving”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Jayaram- Lindström et al., 2008
Citations
Cites
1 retracted
Treatment for amphetamine dependence and abuse
Srisurapanont, M., Jarusuraisin, N., & Kittirattanapaiboon, P. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003022 · Cited by 77
RetractedThe fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222
A psychomotor stimulant theory of addiction.
Wise, R. A., & Bozarth, M. A. (1987) · Psychological Review · doi:10.1037/0033-295x.94.4.469 · Cited by 2,747
Central Catecholamine Neuron Systems: Anatomy and Physiology of the Dopamine Systems
Moore, R. Y., & Bloom, F. E. (1978) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.01.030178.001021 · Cited by 926
Measuring Alcohol Consumption: Psychosocial and Biochemical Methods
(1992) · Humana Press eBooks · doi:10.1007/978-1-4612-0357-5 · Cited by 504
The development of a cocaine craving questionnaire
Tiffany, S. T., Singleton, E., Haertzen, C. A., & Henningfield, J. E. (1993) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(93)90042-o · Cited by 435
Neurobiology of addiction: treatment and public policy ramifications
Dackis, C., & O'Brien, C. (2005) · Nature Neuroscience · doi:10.1038/nn1105-1431 · Cited by 267
Naltrexone-induced alterations in human ethanol intoxication
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.10.1463 · Cited by 254 · cited 1×
“It has been established (13, 19, 20) that the therapeutic effect of naltrexone does not result from any nonspecific effect, such as a pharmacokinetic interaction.”
BackgroundKing, A. C., Volpicelli, J. R., Frazer, A., & O'Brien, C. P. (1997) · Psychopharmacology · doi:10.1007/s002130050156 · Cited by 227
Croop, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830240090013 · Cited by 211
Research works printed but not linked: 5
- United Nations Office on Drugs and Crime, 2005, Drug Report
- Swedish Council for Information on Alcohol and Other Drugs, 2006, Drug Trends in Sweden
- Srisurapanont M, 2001, Cochrane Database Syst Rev, 4, D003022
- Sobell LC, 1992, Measuring Alcohol Consumption, 44
- Lee MC, 1988, J Nucl Med, 29, 1207
Cited by
Courtney, K. E., & Ray, L. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.003 · Cited by 498
“The third trial found support for reduced amphetamine use and greater abstinence rates with naltrexone treatment (50 mg) in a sample of amphetamine-dependent individuals (Jayaram-Lindstrom et al., 2008).”
BackgroundLingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“One RCT reported that naltrexone (50 mg/day) significantly increased the number of amphetamine-negative urines compared with placebo (Jayaram-Lindström et al., 2008) (Ib).”
BackgroundResponding to global stimulant use: challenges and opportunities
Farrell, M., Martin, N. K., Stockings, E., Bórquez, A., Cepeda, J. A., Degenhardt, L., Ali, R., Tran, L. T., Rehm, J., Torrens, M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32230-5 · Cited by 310
Everitt, B. J. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12644 · Cited by 318
“…greater than those of naltrexone, which has been in clinical use for some years to treat alcohol dependence, and also to diminish cue-induced alcohol and cocaine craving (Volpicelli et al., 1992; Davidson et al., 1999; Palfai et al., 1999; Franck et al., 2008; Jayaram-Lindstrom et al., 2008).”
BackgroundBupropion and naltrexone in methamphetamine use disorder
Trivedi, M. H., Walker, R., Ling, W., dela Cruz, A., Sharma, G., Carmody, T., Ghitza, U. E., Wahle, A., Kim, M., Shores-Wilson, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2020214 · Cited by 281
Metadata
- Authors
- Jayaram-Lindström, N., Hammarberg, A., Beck, O., & Franck, J.
- Venue
- American Journal of Psychiatry
- Published
- 2008-11
- Volume
- 165
- Issue
- 11
- Pages
- 1442-1448
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2116763568
- Cited by
- 185
- References
- 26
- Citations by year
- 2025: 11 · 2024: 8 · 2023: 6 · 2022: 8 · 2021: 6 · 2020: 12 · 2019: 5 · 2018: 11 · 2017: 11 · 2016: 9 · 2015: 17 · 2014: 18 · 2013: 15 · 2012: 16
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- naltrexone, amphetamine dependence, pharmacotherapy, relapse prevention, abstinence, craving, urine drug testing, medication adherence
- MeSH terms
- Adult, Amphetamine, Double-Blind Method, Female, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Substance Withdrawal Syndrome, Substance Abuse Detection, Survival Analysis, Treatment Outcome, Amphetamine-Related Disorders, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.1176/appi.ajp.2008.08020304
- The paper
- Jayaram-Lindström, N., Hammarberg, A., Beck, O., & Franck, J. (2008). Naltrexone for the Treatment of Amphetamine Dependence: A Randomized, Placebo-Controlled Trial. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2008.08020304
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.